Karyopharm Therapeutics Inc. (KPTI)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15M 30M 45M Q3 '24: 38.8M Q4 '24: 30.5M Q1 '25: 30M Q2 '25: 37.9M Q3 '25: 44M Q4 '25: 34.1M Q1 '26: 35.1M Q2 '26: 33.4M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Gross Profit Quarterly

0 5M 10M 15M Q3 '19: 12.1M Q3 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -26.3M Q4 '24: -31.3M Q1 '25: -33.3M Q2 '25: -24.4M Q3 '25: -15.2M Q4 '25: -17.8M Q1 '26: -26.8M Q2 '26: -22.5M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '24: -32.1M Q4 '24: -30.8M Q1 '25: -23.5M Q2 '25: -37.3M Q3 '25: -33.1M Q4 '25: -102.2M Q1 '26: -22.4M Q2 '26: -67M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Cost of Revenue Quarterly

0 350K 700K 1.1M Q3 '19: 1M Q3 '19

Operating Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '24: -19.5M Q4 '24: -25.8M Q1 '25: -39M Q2 '25: -18.7M Q3 '25: -5.9M Q4 '25: -11.8M Q1 '26: -22.7M Q2 '26: -24.9M Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Free Cash Flow Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '24: -43.9M Q2 '24: -38.5M Q3 '24: -19.5M Q4 '24: -25.9M Q1 '25: -39M Q2 '25: -18.7M Q3 '25: -5.9M Q4 '25: -11.8M Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 10K 20K 30K Q1 '24: 7.7K Q2 '24: 10.3K Q3 '24: 8.3K Q1 '25: 8.5K Q2 '25: 8.6K Q3 '25: 8.7K Q1 '26: 24.7K Q2 '26: 28.9K Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q3 '21: -2.75 Q4 '21: -1.65 Q1 '22: -1.41 Q2 '22: -1.32 Q3 '22: -1.08 Q4 '22: -2.02 Q1 '23: -1.79 Q2 '23: -1.46 Q3 '21 Q4 '21 Q1 '22 Q2 '22 Q3 '22 Q4 '22 Q1 '23 Q2 '23

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.